EyenoviaEYEN
EYEN
About: Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Employees: 57
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more call options, than puts
Call options by funds: $30K | Put options by funds: $12K
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
12.36% less ownership
Funds ownership: 17.32% [Q3] → 4.96% (-12.36%) [Q4]
22% less funds holding
Funds holding: 49 [Q3] → 38 (-11) [Q4]
59% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 17
88% less capital invested
Capital invested by funds: $6.88M [Q3] → $802K (-$6.08M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
22%
upside
Avg. target
$2
22%
upside
High target
$2
22%
upside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
HC Wainwright & Co. Matthew Caufield 26% 1-year accuracy 16 / 62 met price target | 22%upside $2 | Neutral Reiterated | 6 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)(3)(A)(iii), the low priced stocks rule.
Neutral
GlobeNewsWire
2 weeks ago
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives
Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needs
Neutral
GlobeNewsWire
1 month ago
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device
Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercialization
Neutral
GlobeNewsWire
1 month ago
Eyenovia Announces 1-for-80 Reverse Stock Split
Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternatives
Neutral
GlobeNewsWire
1 month ago
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders
Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20th
Neutral
GlobeNewsWire
2 months ago
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives
Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60% Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60%
Neutral
GlobeNewsWire
3 months ago
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 40,170,050 shares of common stock in a registered direct offering at a combined offering price of $0.0969 per share and accompanying warrants. The warrants will have an exercise price of $0.0969 per share, will be exercisable commencing six months from the date of issuance or, if required by The Nasdaq Capital Market, upon receipt of approval of the Company's stockholders, and will expire five years from the initial exercise date. The closing of the offering is expected to take place on or about December 9, 2024, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
3 months ago
Eyenovia Provides Update on Restructuring Efforts
Avenue Capital agrees to Company's deferral of principal and interest payments on its outstanding debt until the end of February 2025
Negative
Zacks Investment Research
3 months ago
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
Negative
Benzinga
3 months ago
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia.
Charts implemented using Lightweight Charts™